Agennix Nets $105M in Share Offer to Develop Talactoferrin

Agennix AG grossed €78.4 million (US$107.8 million) – about €76 million net of expenses – in a combined rights offering and private placement that will enable it to continue development of its lead drug candidate, talactoferrin, which is being studied in cancer and sepsis. (BioWorld Today)